 'Gene,' 'DNA,' 'Mutation,' 'Genomic,' and 'Breast Cancer' were used as search terms for genomic policies.
 Each coverage policy was reviewed to identify the specific test, evidences considered (if provided) and the policy decision.
 We also reviewed whether the test was cleared or approved by FDA.
 Data were analyzed descriptively.  The coverage for disease-related genomic testing is low, mainly due to the lack of adequate clinical evidence.
 A variation in coverage was evident among insurers, as some of the insurers are willing to reimburse despite limited clinical evidence.
 Acceptance by oncologists seems to be important for insurers. For example, Oncotype Dx ® is not approved by FDA, but is favored for reimbursement by all insurers as it was adopted widely by the oncologists based on its clinical utility.  Additional studies on variability among coverage policies for cuttingedge technologies such as personalized medicine is warranted.
 Since recent FDA guidance recommended contemporaneous 4 approval of companion diagnostics and its corresponding therapeutic product, sponsors are likely to intensify innovation in this domain 
REFERENCES Insurance Coverage Policies for Companion Diagnostics in Breast Cancer
Jha RK, Singh A, Kapoor A, Gupta J Optum Global Solutions, Noida, India RESULTS  A total of 14 products has been cleared or approved by US FDA as companion diagnostic tools; these include 10 different HER2 tests, ProSigna ® , MammaPrint ® , GeneSearch ® , and Dako TOP2A.
 Among all policies identified, overall 7 unique tests were discussed for diagnosis, prognosis and risk assessment of breast cancer ( Table 1) . Of these, only 3 were cleared or approved by FDA, while 4 others were identified from the policies.
 Majority of these diagnostic tests (6/7) were indicated for measuring the recurrence risk of breast cancer.
 Of the 7 tests discussed, Oncotype Dx ® and Mammaprint ® were the only two test that are reimbursed by various private insurers.  Across policies, majority of these tests (5/7) were deemed investigational and not medically necessary. The insurers did not recognize the proposed technology of significant value from diagnostic point of view and was not willing to reimburse (Fig. 1) .
 In general, policy coverage decisions were guided by evidence from clinical trials, oncologists' perceptions, and FDA decision (Fig. 1) .
